<DOC>
	<DOCNO>NCT02751918</DOCNO>
	<brief_summary>Anetumab ravtansine develop treatment patient recurrent platinum-resistant ovarian cancer . The purpose propose trial identify maximum tolerate dose anetumab ravtansine could safely combine pegylated liposomal doxorubicin indication .</brief_summary>
	<brief_title>Phase Ib Study Anetumab Ravtansine Combination With Pegylated Liposomal Doxorubicin Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Subject must provide sign informed consent screening procedure . Subject must female age â‰¥18 year . Subject must histologically confirm , locally invasive metastatic , predominantly epithelial platinumresistant ovarian , fallopian tube , primary peritoneal cancer . Subject must recurrent , platinumresistant cancer Subjects must provide sample archival tumor tissue ( tissue block least 5 formalinfixated , paraffinembedded [ FFPE ] slide ) time study . Subject must life expectancy least 12 week . Subjects must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Subject must adequate bone marrow , kidney liver function coagulation , assessed standard laboratory test result Women reproductive potential must negative serum beta human chorionic gonadotropin ( beta HCG ) pregnancy test obtain within 7 day start anetumab ravtansine . Women reproductive potential female subject postmenopausal permanently sterilize ( e.g. , tubal occlusion , hysterectomy , bilateral salpingectomy ) . Women reproductive potential must agree consistently use adequate contraception / birth control signing inform consent 60 day last administration last study drug . The investigator designate associate advise subject achieve adequate contraception . Due lack adequate reproductive toxicity data anetumab ravtansine , subject must concomitantly use 2 form adequate contraception . Subjects previous concurrent cancer distinct primary site histology cancer evaluate study . Subjects history current evidence bleeding disorder within 4 week start anetumab ravtansine . Subjects new progressive brain meningeal spinal metastasis . Subjects QTc ( QT interval correct heart rate ) &gt; 480 m , heart rate &gt; /=100 bpm , LVEF ( leave ventricular ejection fraction ) &lt; 50 % , history current evidence uncontrolled cardiovascular disease . Women pregnant breastfeeding . Subjects major surgery significant trauma within 4 week start anetumab ravtansine . Subjects organ allograft hematopoietic transplantation . Subjects history hypersensitivity study drug , antigen . Subjects history human immunodeficiency virus ( HIV ) infection , active hepatitis B C virus infection require treatment . Subjects nonhealing serious wound , ulcer , bone fracture unrelated primary tumor . Subjects corneal epitheliopathy eye disorder may predispose subject druginduced corneal epitheliopathy . Subjects received systemic antitumor therapy radiotherapy target lesion within 4 week start anetumab ravtansine Subjects unresolved CTCAE ( Common Terminology Criteria Adverse Events , v4.03 ) Grade &gt; 1 toxicity previous anticancer therapy . Subjects receive GCSF ( granulocyte colonystimulating factor ( ) ) , GMCSF ( granulocyte macrophagestimulating factor ( ) ) , erythropoietinstimulating agent within 3 week start screen . Subjects receive chemotherapy anthracycline agent cumulative dose 550 mg/m2 . Subjects received investigational drug treatment outside study within 4 week start anetumab ravtansine . Use strong CYP3A4 inhibitor strong CYP3A4 inducer oral parenteral anticoagulation therapy start within 2 week start anetumab ravtansine EoT ( end treatment ) visit .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Mesothelin-expressing platinum-resistant cancer</keyword>
</DOC>